Hepatitis C Virus RNA Elimination and Development of Resistance in Replicon Cells Treated with BMS-790052

Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1

(2011) Richard E. Nettles et al.   HEPATOLOGY

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations

(2011) Robert A. Fridell et al.   HEPATOLOGY

Colony-forming assays reveal enhanced suppression of hepatitis C virus replication using combinations of direct-acting antivirals

(2011) Emily J.S. Graham et al.   JOURNAL OF VIROLOGICAL METHODS

Future hepatitis C virus treatment: interferon-sparing combinations

(2011) Edward Gane   LIVER INTERNATIONAL

Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System

(2010) R. A. Fridell et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Hepatitis C virus replication cycle

(2010) Ralf Bartenschlager et al.   JOURNAL OF HEPATOLOGY

A perspective on modelling hepatitis C virus infection

(2010) J. Guedj et al.   JOURNAL OF VIRAL HEPATITIS

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE

Hepatitis C Treatment: current and future perspectives

(2010) Saira Munir et al.   Virology Journal

Identification of Hepatitis C Virus NS5A Inhibitors

(2009) J. A. Lemm et al.   JOURNAL OF VIROLOGY

Effect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In Vivo

(2009) J. M. Cuevas et al.   JOURNAL OF VIROLOGY

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

(2008) M. F. McCown et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY